A DeepPurpose model to estimate inhibition constants (Ki) from molecular graphs and protein sequences was trained and whether those predictions could be aligned empirically with measured IC50 values without treating Ki and IC50 as interchangeable was asked.
Abstract
Drug target affinity models return the endpoint on which they are trained, whereas medicinal chemistry decisions are often made with a different assay readout. Here, we trained a DeepPurpose model to estimate inhibition constants (Ki) from molecular graphs and protein sequences and asked whether those predictions could be aligned empirically with measured IC50 values without treating Ki and IC50 as interchangeable. A BindingDB-trained checkpoint retained useful cross-target ranking on the Davis kinase benchmark without Davis training data (concordance index 0.860). We then rebuilt the Ki training set from ChEMBL 37 records coded as Binding assays (assay_type = 'B'), after removing censored records and targets with poor replicate reproducibility. This reduced median fold error from 16.35x to 9.23x on a leakage-cleaned kinase panel and from 15.30x to 7.90x on a 14-target non-kinase panel before any IC50 calibration. Similarity-guided leave-one-out calibration further reduced the non-kinase panel median error to 3.12x for the original checkpoint and 3.22x for the ChEMBL checkpoint at Tanimoto T = 0.6. Because retraining removed a substantial part of the apparent correction, we interpret the calibration as a target- and chemistry-dependent empirical offset between model output and IC50 assay space, not as a mechanistic Ki-to-IC50 conversion. In a separate project-level stratification of public records, median replicate variability was 2.41x for the subset classified as biochemical Ki and 3.30x for biochemical IC50; a small-sample correction placed the Ki variability nearer 2.8x. These values provide an empirical scale for the remaining calibration error rather than a theoretical performance limit. Similarity, rather than the number of calibrators, governed the main accuracy coverage trade-off. The resulting values are surrogate IC50 estimates for cross-target triage; within-target ranking remains a limitation of the present architecture.
Drug-target affinity (DTA) prediction is widely used to prioritize candidate compounds before costly experimental screening. DTA models are often compared under a single data split, even though deployment may require extrapolation to new chemical series, new protein targets, or both. We ask whether the distribution shi...
Minjae Chung, Clara Li, M. Muthukumaran et al.· 0 citations
A transparent pre-screen can prioritise compounds ahead of structure-based calculation at a fraction of its cost, and the uncertainty and applicability-domain terms act as an abstention mechanism rather than an accuracy gain, and that abstention is not free.
Overall, the results show that classifier design and optimisation account for a substantial portion of the improvement over MolTrans, while the contribution of cross-modal architectural components is optimisation-sensitive and dataset-dependent.
Hao Pang, Fiseha B. Tesema, Tian-Xiang Cui et al.· BMC Bioinformatics· 0 citations
This work presents a model validation framework consisting of five recommendations that would enable the community to move beyond aggregate metrics toward understanding where and why molecular property prediction models fail, and connects evaluation choices to real-world applications and case studies encountered in pha...
Srijit Seal, Akshat Shirish Zalte, David Alencar Araripe et al.· bioRxiv· 0 citations
HelixDTA is introduced, a deep learning framework featuring a parallel dual-branch architecture that independently learns representations from two distinct but complementary modalities: sequence context and complete target structures that demonstrates significant potential to empower precision drug design and accelerat...
Shang Lou, Xu-Hua Li, Yu-Jie Peng et al.· Journal of Chemical Informat...· 0 citations
Objective To systematically evaluate the predictability of drug chemical structures against the complete set of MedDRA Preferred Terms (PTs), construct a comprehensive structure– adverse reaction landscape, validate the utility of molecular fingerprint representations in pan-screening tasks, and establish quantitative...
Wei Jiang, Xiang'e Jian, Jie-Kai Hu et al.· bioRxiv· 0 citations
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.